Comparative clinical trial of the tolerability, patient acceptability and efficacy of two transdermal glyceryl trinitrate patches ('Deponit' 5 and 'Transiderm-Nitro' 5) in patients with angina pectoris.
A randomized two-period crossover trial was carried out to compare the efficacy, tolerability and patient acceptability of two transdermal ('patch') formulations of glyceryl trinitrate. 'Deponit' 5 and 'Transiderm-Nitro' 5, both designed to deliver 5 mg glyceryl trinitrate in 24 hours. All patients were treated for 4 weeks with each of the formulations, changed once per day. Forty-seven patients entered the trial and all completed both phases of treatment. Both drugs resulted in highly significant mean reductions in angina attack frequency, the reduction being significantly greater with 'Deponit'. Similarly, mean sublingual glyceryl trinitrate consumption was also reduced; again, the greater reduction with 'Deponit' was significant. In terms of effectiveness, 'Deponit' was preferred to 'Transiderm-Nitro' by 19 patients, whilst only 5 patients preferred 'Transiderm-Nitro' (p less than 0.01). In terms of ease of application, comfort, appearance and adhesion (assessed in relation to daytime, night-time, washing, bathing and exercising), there were no appreciable or significant differences between patients' assessments of the two forms. Neither treatment had any appreciable effect on heart rate or blood pressure. Both formulations were very well tolerated, with very few reported side-effects.